Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Accumulated Expenses (2023 - 2025)

China SXT Pharmaceuticals (SXTC) has 3 years of Accumulated Expenses data on record, last reported at $2.9 million in Q1 2025.

  • For Q1 2025, Accumulated Expenses rose 6.11% year-over-year to $2.9 million; the TTM value through Mar 2025 reached $2.9 million, up 6.11%, while the annual FY2025 figure was $2.9 million, 6.11% up from the prior year.
  • Accumulated Expenses reached $2.9 million in Q1 2025 per SXTC's latest filing, up from $2.8 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $2.9 million in Q1 2025 and bottomed at $622526.0 in Q1 2023.
  • Average Accumulated Expenses over 3 years is $2.1 million, with a median of $2.8 million recorded in 2024.
  • Peak YoY movement for Accumulated Expenses: soared 344.71% in 2024, then rose 6.11% in 2025.
  • A 3-year view of Accumulated Expenses shows it stood at $622526.0 in 2023, then skyrocketed by 344.71% to $2.8 million in 2024, then rose by 6.11% to $2.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accumulated Expenses were $2.9 million in Q1 2025, $2.8 million in Q1 2024, and $622526.0 in Q1 2023.